ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Madrid, MD, ESP:

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations....

Enrolling
Metastatic Uveal Melanoma
Drug: DYP688

Phase 1, Phase 2

Novartis
Novartis

Madrid, Spain and 10 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Madrid, Spain and 47 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Madrid, Spain and 154 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp
Drug: Tebentafusp with Pembrolizumab

Phase 2, Phase 3

Immunocore
Immunocore

Madrid, Spain and 70 other locations

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Active, not recruiting
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 2

Pfizer
Pfizer

Madrid, Spain and 62 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Madrid,, Madrid, Spain and 112 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Madrid, Spain and 227 other locations

Locations recently updated

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Madrid, Spain and 31 other locations

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Pembrolizumab

Phase 2

Mural Oncology

Madrid, Spain and 43 other locations

Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without prev...

Active, not recruiting
Metastatic Melanoma
Brain Metastases
Drug: binimetinib
Radiation: Whole brain radiation therapy

Phase 2

Grupo Español Multidisciplinar de Melanoma

Madrid, Spain and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems